Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

"M3-M6" Molecular Response Evolution As Early Predictor of Outcome Considering Generic Vs Branded TKIs for Chronic Myeloid Leukemia (CML): An Argentine Multicentric Study

Isabel Amanda Giere, PhD M.Sc, María Jose Mela Osorio, MD, Federico Andrés Klosowski, Mariana Debus, Federico Sackmann, MD, Miguel A Pavlovsky, MD, Isolda Fernandez, MD, Elena Beatriz Moiraghi, MD, Ana Inés Varela, MD, Mariel Ana Perez, MD, Julio M. Pose Cabarcos, MD, Georgina Bendek, MD, Romina Mariano, MD, Silvina Palmer, MD, Alicia Enrico, MD, Isabel Cristina Annetta, MD, Andres L. Brodsky, MD PhD, Dante Intile, Statistic MD, Carolina Pavlovsky, MD

Blood (2016) 128 (22): 5445.

https://doi.org/10.1182/blood.V128.22.5445.5445

Published: 2016

Journal Articles

Real-World Data from Long Term Follow-up in Chronic Myeloid Leukemia (CML) Patients (PTS) Treated with Imatinib. Predictive Factors for Achievement of Deep Molecular Responses and for Failure

María Jose Mela Osorio, MD, Isabel Amanda Giere, PhD M.Sc, Isolda Fernandez, MD, Miguel A Pavlovsky, MD, Guillermina Remaggi, MD, Federico Sackmann, Dante Intile, Statistic, Carolina Pavlovsky, MD

Blood (2015) 126 (23): 5169.

https://doi.org/10.1182/blood.V126.23.5169.5169

Published: 2015

Journal Articles

Chronic Myeloid Leukemia (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study

Isabel Amanda Giere, PhD M.Sc, María Jose Mela Osorio, MD, Federico Andrés Klosowski, Mariana Debus, Ana Inés Varela, MD, Elena Beatriz Moiraghi, MD, Miguel A Pavlovsky, MD, Isolda Fernandez, MD, Dante Intile, Statistic, Carolina Pavlovsky, MD

Blood (2015) 126 (23): 1590.

https://doi.org/10.1182/blood.V126.23.1590.1590

Published: 2015

Journal Articles

Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience

Carolina Pavlovsky, MD, Isolda Fernandez, MD, Miguel A Pavlovsky, MD, Adriana Galeano, Federico Sackmann, Dante Intile, Statistic, Astrid Pavlovsky, MD

Blood (2015) 126 (23): 1739.

https://doi.org/10.1182/blood.V126.23.1739.1739

Published: 2015

Journal Articles

Ruxolitinib In Myelofibrosis (MF) Patients Through Compassionate Use Program (CUP). Argentinian Experience

Blood (2013) 122 (21): 5247.

https://doi.org/10.1182/blood.V122.21.5247.5247

Published: 2013

Journal Articles

Decitabine in Myelodysplastic Syndromes: Argentine Initial Multi-Institutional Clinical Experience

Marcelo Iastrebner, MD, Virginia Prates, MD, Jorge Arbelbide, MD, Isolda Fernandez, MD, Gabriela Flores, MD, Gustavo Milone, MD, Federico Sackmann, MD, Silvia Saba, MD, Sergio Orlando, MD, Alfredo Basso, MD, Astrid Pavlovsky, MD, Gustavo Taborda, MD, Jorge Korin, MD, Julio Pose, MD

Blood (2008) 112 (11): 5086.

https://doi.org/10.1182/blood.V112.11.5086.5086

Published: 2008

Journal Articles

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Carolina Pavlovsky, MD, Santiago Pavlovsky, MD PhD, Maria L. Pardo, MD, Sandra Sapia, MD, Mariela Monreal, MD, Claudia Corrado, MDd, Miguel A. Pavlovsky, MD, Isolda Fernandez, MD, Mariana Juni, MS

Blood (2006) 108 (11): 4968.

https://doi.org/10.1182/blood.V108.11.4968.4968

Published: 2006

Journal Articles

Impact of FLT3 Mutational Status as Prognostic Factor in Acute Myeloid Leukemia Patients from Argentina and Uruguay.

Isabel Giere, PhD, Angel Chacon, MD, Rosario Uriarte, PhD, Virginia Lombardi, PhD, Isolda Fernandez, MD, Fernanda Garcia Reinoso, Ph.D, Rosana Bonomi, MD, Maria Zubillaga, PhD, Hugo Giordano, MD, Laura Pardo, PhD, Sandra Sapia, MD, Mariela Monreal, Ph.D, Lem Martinez, MD, Santiago Pavlovsky, MD, PhD

Blood (2005) 106 (11): 4494.

https://doi.org/10.1182/blood.V106.11.4494.4494

Published: 2005

NARROW

"M3-M6" Molecular Response Evolution As Early Predictor of Outcome Considering Generic Vs Branded TKIs for Chronic Myeloid Leukemia (CML): An Argentine Multicentric Study

Real-World Data from Long Term Follow-up in Chronic Myeloid Leukemia (CML) Patients (PTS) Treated with Imatinib. Predictive Factors for Achievement of Deep Molecular Responses and for Failure

Chronic Myeloid Leukemia (CML): BCR-ABL Transcript Levels Halving Time and Relative Reduction Ratio at Months 3 As New Predictors of Outcome. an Argentine Pilot Study

Abbreviated Regimen with 4 Cycles of Fludarabine, Cyclophosphamide and Rituximab (FCR) in Physically Fit Patients with Chronic Lymphocytic Leukemia Who Achieve Early Complete Remission with Undetectable Minimal Residual Disease: Safety and Efficacy Follow-up Results of a Single Center Experience

Ruxolitinib In Myelofibrosis (MF) Patients Through Compassionate Use Program (CUP). Argentinian Experience

Decitabine in Myelodysplastic Syndromes: Argentine Initial Multi-Institutional Clinical Experience

Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL). A Single Center Experience.

Impact of FLT3 Mutational Status as Prognostic Factor in Acute Myeloid Leukemia Patients from Argentina and Uruguay.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only